CG Oncology
phase study for high risk exposed and naive planned study | CG Oncology
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2024
Slide
27 of 45
Similar slides by CG Oncology
See diffirences between slides (animation)
IPO
March 2024
phase adjuvant following versus observation following for intermediate risk | CG Oncology
IPO
March 2024
phase for high risk unresponsive containing unresponsive penis | CG Oncology
IPO
March 2024
phase for high risk unresponsive | CG Oncology
Related slides by other companies
Equillium
Investor Presentation
February 2024
phase study of in adults with moderate to severe potential target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Genprex
Investor Presentation
October 2022
| Genprex
Equillium
Investor Presentation
December 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Erasca
Investor Presentation
August 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io